Montrouge, March 7, 2018 DBV Technologies to Present at the Barclays Global Healthcare Conference DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced that Susanna Mesa, Chief Business Officer, will present and host investor meetings at th...Read More
Doubleview Provides Plans for Launch of 2018 Field Season Vancouver, British Columbia (FSCwire) - Doubleview Capital Corp. (“Doubleview”) (TSX-V: DBV) reports it has completed a comprehensive review of historic and recent work on its Hat gold-copper-cobalt-silver porphyry project, w...Read More
Press ReleaseMontrouge, France, February 26, 2018 ...Read More
DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients Positive preliminary results support Viaskin Milk's potential as the first treatment for patients suffering from IgE-mediated cow's milk protein allergy (CMPA), an unmet medical...Read More
Press Release Montrouge, France, February 20, 2018 DBV Technologies Reports December 31, 2017 Cash Position DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced its cash and cash equivalents as of December 31, 2017. Cash and cash eq...Read More
Press Release Montrouge, France, February 14, 2018 ...Read More
Communiqué de presseMontrouge, France, le 12 février 2018 (15h00 CET) DBV Technologies présente de nouveaux résultats lors du Congrès Annuel 2018 de l'AAAAI/WAO concernant sa plateforme Viaskin ...Read More
Press ReleaseMontrouge, France, February 1, 2018 DBV Technologies to Attend Upcoming Investor Conferences ...Read More
Doubleview (TSX-V: DBV) Acquires More Mineral Tenure at the Hat Gold, Copper, Silver and Cobalt Porphyry Project Vancouver, British Columbia (FSCwire) - Doubleview Capital Corp. (“Doubleview”) (TSX-V: DBV) is pleased to announce that it has acquired an additional 1,652 hectare...Read More
Doubleview Capital Corp. (TSX-V: DBV) - Provides Hat Gold-Copper Porphyry Deposit Update Vancouver, British Columbia (FSCwire) - Doubleview Capital Corp. (“Doubleview”) (TSX-V: DBV) is pleased to announce an exploration update from its Hat porphyry project, where drilling in the pas...Read More
AMF REGULATED INFORMATIONMontrouge, France, January 16, 2018 Half-Year Report on DBV Technologies Liquidity Contract with Natixis Under the liquidity contract between DBV TECHNOLOGIES and NATIXIS, the following assets appeared on the liquidity account as of December 29, 2017: &...Read More
Press ReleaseMontrouge, France, January 3, 2018 DBV Technologies to Present at the 36th Annual J.P. Morgan Healthcare Conference &...Read More
Doubleview Capital Corp. (TSX-V: DBV) Closes Private Placement Financing Vancouver, British Columbia (FSCwire) - Doubleview Capital Corp. (“Doubleview”) (TSX-V: DBV) is pleased to announce that it has closed its fully subscribed non-brokered private placement financing of 2,086,666...Read More
Doubleview Capital Corp. (TSX-V: DBV) Announces Private Placement Financing Vancouver, British Columbia (FSCwire) - Doubleview Capital Corp. (“Doubleview”) (TSX-V: DBV) is pleased to announce a fully subscribed non-brokered private placement financing of 2,086,666 flow through units...Read More
Press ReleaseMontrouge, France, December 4, 2017 DBV Technologies CEO, Chairman, and Co-Founder, Dr. Pierre-Henri Benhamou Recognized for His Lasting Impact on the Food Allergy Community and Research Advancement by FARE (Food Allergy Research & Education) DBV Technologies...Read More
MONTROUGE, FRANCE--(Marketwired - November 28, 2017) - DBV Technologies (EURONEXT PARIS: DBV) (ISIN: FR0010417345) (NASDAQ: DBVT) today announced that David Schilansky, Chief Operating Officer & Deputy Chief Executive Officer, and Susanna Mesa, SVP, Strategy, will host investor meetings at...Read More
VANCOUVER, British Columbia, Nov.20, 2017(GLOBE NEWSWIRE) -- Doubleview Capital Corp. (“Doubleview”) (TSX-V:DBV) is pleased to announce that it has closed its fully subscribed non-brokered private placement financing of 10,000,000 units (the “Units”) at a price of $0....Read More
Press Release Montrouge, France, November 14, 2017 DBV Technologies Announces Publication of Positive Data from Phase IIb Trial and Long-Term Study of Viaskin Peanut in the Journal of the American Medical Association Primary endpoint of Phase IIb study was met after 12 months of treatment Lon...Read More
VANCOUVER, British Columbia, Nov.01, 2017(GLOBE NEWSWIRE) -- Doubleview Capital Corp. ("Doubleview") (TSX-V:DBV) is pleased to announce a fully subscribed non-brokered private placement financing of 10,000,000 units (the "Units") at a price of $0.05 per Unit for gross proceeds of $500,000. Each...Read More
Press Release Montrouge, France, October 20, 2017 DBV Technologies Announces Topline Results of Phase III Clinical Trial in Peanut-Allergic Patients Four to 11 Years of Age DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced topline results from t...Read More